We will see, breast cancer is probably more enforceable than all cancers, the 2011 study was the largest study, 2,254 humans, making the biggest connections, the first really making the connection known to everyone, maybe the first to try a ccr5 antagonist with breast cancer--I would need to check--with pestell being the first to file for a patent, but here is 1998 paper below, rantes breast cancer. All in all, gaining the ctc use will be worth it in the end in my opinion, without RP I don't believe they would be using ctc technology, which should speed up the approval significantly.

https://www.ncbi.nlm.nih.gov/pubmed/10493525

https://www.ncbi.nlm.nih.gov/pubmed/11861388
expression of the CCR5 RANTES

CTC/ccr5 patent application, which I don't believe RP listed in the paperwork requesting related ccr5 patents during original due diligence (I will have to find it again)
Richard Pestell, Massimo Cristofanilli, Xuanmao Jiao
https://patents.google.com/patent/WO2016209926A1/en

Also pfizer patent ccr5/cancer application but later than pestell
https://patents.google.com/patent/US20180289689A1/en